Myeloid molecular characteristics of human γδ T cells support their acquisition of tumor antigen-presenting capacity

Cancer Immunology, Immunotherapy

Volumn 64, Issue 8, 2015, Pages 941-949

  Muto, Masato ^a,b   Baghdadi, Muhammad ^a   Maekawa, Ryuji ^b   Wada, Haruka ^a   Seino, Ken Ichiro ^a  

^a HOKKAIDO UNIVERSITY   (Japan)

^b Medinet Co Ltd   (Japan)

Author keywords

Antigen presenting capacity; C EBP ; CD36; Myeloid; Zoledronate; T cells

Indexed keywords

B7 ANTIGEN; CCAAT ENHANCER BINDING PROTEIN ALPHA; CD11B ANTIGEN; CD36 ANTIGEN; CD8 ANTIGEN; CD86 ANTIGEN; GLYCOPROTEIN P 15095; I KAPPA B KINASE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERCELLULAR ADHESION MOLECULE 1; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MELAN A; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; T LYMPHOCYTE RECEPTOR; TRANSCRIPTION FACTOR GATA 3; TRANSCRIPTION FACTOR PU 1; TUMOR ANTIGEN; 4 (4 FLUOROPHENYL) 2 (4 METHYLSULFINYLPHENYL) 5 (4 PYRIDYL)IMIDAZOLE; 6 CHLORO 8 NICOTINAMIDO BETA CARBOLINE; CCAAT ENHANCER BINDING PROTEIN; CEBPA PROTEIN, HUMAN; FUSED HETEROCYCLIC RINGS; IMIDAZOLE DERIVATIVE; LYMPHOCYTE ANTIGEN RECEPTOR; PYRIDINE DERIVATIVE;

ANTIGEN PRESENTATION; ANTIGEN PRESENTING CELL; ANTIGEN SPECIFICITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER IMMUNOTHERAPY; CD8+ T LYMPHOCYTE; CELL LINEAGE; CONFOCAL MICROSCOPY; CONTROLLED STUDY; GAMMA DELTA T LYMPHOCYTE; HUMAN; HUMAN CELL; PHAGOCYTOSIS; PHENOTYPE; PRIORITY JOURNAL; RECEPTOR UPREGULATION; SIGNAL TRANSDUCTION; T LYMPHOCYTE ACTIVATION; ANTAGONISTS AND INHIBITORS; CELL DIFFERENTIATION; CYTOTOXICITY; DRUG EFFECTS; GENETICS; IMMUNOLOGY; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; METABOLISM; NEOPLASMS; PROCEDURES; T LYMPHOCYTE; TUMOR CELL LINE; UPREGULATION;

ANTIGEN PRESENTATION; ANTIGENS, CD36; ANTIGENS, NEOPLASM; CCAAT-ENHANCER-BINDING PROTEINS; CD8-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL LINEAGE; CYTOTOXICITY, IMMUNOLOGIC; HETEROCYCLIC COMPOUNDS, 3-RING; HUMANS; IMIDAZOLES; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MART-1 ANTIGEN; MYELOID CELLS; NEOPLASMS; NF-KAPPA B; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHAGOCYTOSIS; PYRIDINES; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; SIGNAL TRANSDUCTION; T-LYMPHOCYTES; UP-REGULATION;

EID: 84937973946     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-015-1700-x     Document Type: Article

References (28)

1. Kabelitz D, Wesch D, Pitters E, Zöller M (2004) Potential of human gammadelta T lymphocytes for immunotherapy of cancer. Int J Cancer 112(5):727–732
2. Tanaka Y, Morita CT, Tanaka Y (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375:155–158
3. Bennouna J, Bompas E, Neidhardt EM, Rolland F, Philip I, Galéa C, Salot S, Saiagh S, Audrain M, Rimbert M, Lafaye-de Micheaux S, Tiollier J, Négrier S (2008) Phase-I study of Innacell gammadelta, an autologous cell-therapy product highly enriched in gamma9delta2 T lymphocytes, in combination with IL-2, in patients with metastatic renal cell carcinoma. Cancer Immunol Immunother 57(11):1599–1609
4. δ T cells in combination with zoledronic acid and IL-2 to patients with advanced renal cell carcinoma. Cancer Immunol Immunother 60(8):1075–1084
5. Nicol AJ, Tokuyama H, Mattarollo SR, Hagi T, Suzuki K, Yokokawa K, Nieda M (2011) Clinical evaluation of autologous gamma delta T cell-based immunotherapy for metastatic solid tumours. Br J Cancer 105:778–786
6. Nakajima J, Murakawa T, Fukami T, Goto S, Kaneko T, Yoshida Y, Takamoto S, Kakimi K (2010) A phase I study of adoptive immunotherapy for recurrent non-small-lung cancer patients with autologous gammadelta T cells. Eur J Cardiothorac Surg 37:1191–1197
7. Wada I, Matsushita H, Noji S, Mori K, Yamashita H, Nomura S, Shimizu N, Seto Y, Kakimi K (2014) Intraperitoneal injection of in vitro expanded Vγ9Vδ2 T cells together with zoledronate for the treatment of malignant ascites due to gastric cancer. Cancer Med 3(2):362–375
8. Kunzmann V, Bauer E, Wilhelm M (1999) γ/δ T-cell stimulation by pamidronate. N Engl J Med 340:737
9. δ T cells by aminobisphosphonates and induction of antiplasma cell activity in multiple myeloma. Blood 96:384–392
10. Wilhelm M, Kunzmann V, Eckstein S, Reimer P, Weissinger F, Ruediger T, Tony HP (2003) Gammadelta T cells for immune therapy of patients with lymphoid malignancies. Blood 102(1):200–206
11. Abe Y, Muto M, Nieda M (2009) Clinical and immunological evaluation of zoledronate-activated Vgamma9gammadelta T-cell-based immunotherapy for patients with multiple myeloma. Exp Hematol 37:956–968
12. Brandes M, Willimann K, Moser B (2005) Professional antigen-presentation function by human gammadelta T cells. Science 309(5732):264–268
13. Wu Y, Wu W, Wong WM, Ward E, Thrasher AJ, Goldblatt D, Osman M, Digard P, Canaday DH, Gustafsson K (2009) Human gamma delta T cells: a lymphoid lineage cell capable of professional phagocytosis. J Immunol 183(9):5622–5629
14. + T-cell responses to subdominant Epstein Barr virus epitopes: potential for immunotherapy of cancer. J Immunother 32:310–321
15. + T-cell responses to tumor-associated self-antigens. Cancer Immunol Immunother 61:385–396
16. + αβ T cell responses. Proc Natl Acad Sci USA 106(7):2307–2312
17. δ T lymphocytes are licensed for professional antigen presentation by interaction with opsonized target cells. J Immunol 188(4):1708–1716
18. + T cell responses. J Immunol 182(1):193–206
19. + CTL responses and long-term T cell memory. J Leukoc Biol 82(4):829–838
20. Hollis A, Speri B, Graber M, Berg T (2012) The natural product betulinic acid inhibits C/EBP family transcription factors. ChemBioChem 13(2):302–307
21. Albert ML, Pearce SF, Francisco LM, Sauter B, Roy P, Silverstein RL, Bhardwaj N (1998) Immature dendritic cells phagocytose apoptotic cells via alphavbeta5 and CD36, and cross-present antigens to cytotoxic T lymphocytes. J Exp Med 188(7):1359–1368
22. Greenberg ME, Sun M, Zhang R, Febbraio M, Silverstein R, Hazen SL (2006) Oxidized phosphatidylserine-CD36 interactions play an essential role in macrophage-dependent phagocytosis of apoptotic cells. J Exp Med 203(12):2613–2625
23. Ardeshna KM, Pizzey AR, Devereux S, Khwaja A (2000) The PI3 kinase, p38 SAP kinase, and NF-kappaB signal transduction pathways are involved in the survival and maturation of lipopolysaccharide-stimulated human monocyte-derived dendritic cells. Blood 96(3):1039–1046
24. Yoshimura S, Bondeson J, Foxwell BM, Brennan FM, Feldmann M (2001) Effective antigen presentation by dendritic cells is NF-kappaB dependent: coordinate regulation of MHC, co-stimulatory molecules and cytokines. Int Immunol 13(5):675–683
25. Lubick K, Jutila MA (2006) LTA recognition by bovine gammadelta T cells involves CD36. J Leukoc Biol 79(6):1268–1270
26. Ross SE, Radomska HS, Wu B, Zhang P, Winnay JN, Bajnok L, Wright WS, Schaufele F, Tenen DG, MacDougald OA (2004) Phosphorylation of C/EBPalpha inhibits granulopoiesis. Mol Cell Biol 24(2):675–686
27. Qiao L, Zou C, Shao P, Schaack J, Johnson PF, Shao J (2008) Transcriptional regulation of fatty acid translocase/CD36 expression by CCAAT/enhancer-binding protein alpha. J Biol Chem 283(14):8788–8795
28. Meuter S, Eberl M, Moser B (2010) Prolonged antigen survival and cytosolic export in cross-presenting human gammadelta T cells. Proc Natl Acad Sci USA 107(19):8730–8735